An In Vitro Human Skin Test for Predicting Skin Sensitization and Adverse Immune Reactions to Biologics
Toxics · 30.05.2024 · 12 (6) · 401
DOI: 10.3390/toxics12060401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxics, online erschienen am 30.05.2024. Verfasst von Shaheda Sameena Ahmed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Alcyomics Ltd., The Biosphere, Draymans Way, Newcastle Helix, Newcastle Upon Tyne NE4 5BX, UK. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovate UK, Technology Strategy Board, UK Government Advanced Manufacturing Supply Chain Initiative as part of the Biostreamline Project.
Abstract (Originalsprache)
Biologics, including monoclonal antibodies (mAb), have proved to be effective and successful therapeutic agents, particularly in the treatment of cancer and immune-inflammatory conditions, as well as allergies and infections. However, their use carries an inherent risk of an immune-mediated adverse drug reaction. In this study, we describe the use of a novel pre-clinical human in vitro skin explant test for predicting skin sensitization and adverse immune reactions. The skin explant test was used to investigate the effects of therapeutic antibodies, which are known to cause a limited reaction in a small number of patients or more severe reactions. Material and Methods: Immune responses were determined by T cell proliferation and multiplex cytokine analysis, as well as histopathological analysis of skin damage (grades I–IV in increasing severity), predicting a negative (grade I) or positive (grade ≥ II) response for an adverse skin sensitization effect.
Results
T cell proliferation responses were significantly increased in the positive group (p < 0.004). Multiplex cytokine analysis showed significantly increased levels of IFNγ, TNFα, IL-10, IL-12, IL-13, IL-1β, and IL-4 in the positive response group compared with the negative response group (p < 0.0001, p < 0.0001, p < 0.002, p < 0.01, p < 0.04, p < 0.006, and p < 0.004, respectively).
Conclusions
Overall, the skin explant test correctly predicted the clinical outcome of 13 out of 16 therapeutic monoclonal antibodies with a correlation coefficient of 0.770 (p = 0.0001). This assay therefore provides a valuable pre-clinical test for predicting adverse immune reactions, including T cell proliferation and cytokine release, both associated with skin sensitization to monoclonal antibodies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Alcyomics Ltd., The Biosphere, Draymans Way, Newcastle Helix, Newcastle Upon Tyne NE4 5BX, UK.
- National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
- Translational and Clinical Research Institute Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK.
ORCID-Profile: Richard Stebbings
Förderung
- Innovate UK
- Technology Strategy Board
- UK Government Advanced Manufacturing Supply Chain Initiative as part of the Biostreamline Project
Zitieren
APA
Ahmed, S. S., Ahmed, M. M., Ishaq, A., Freer, M., Stebbings, R., & Dickinson, A. M. (2024). An In Vitro Human Skin Test for Predicting Skin Sensitization and Adverse Immune Reactions to Biologics. Toxics, 12(6), 401. https://doi.org/10.3390/toxics12060401
Vancouver
Ahmed SS, Ahmed MM, Ishaq A, Freer M, Stebbings R, Dickinson AM. An In Vitro Human Skin Test for Predicting Skin Sensitization and Adverse Immune Reactions to Biologics. Toxics. 2024;12(6):401. doi:10.3390/toxics12060401
BibTeX
@article{Ahmed2024,
author = {Ahmed, Shaheda Sameena and Ahmed, Mohammed Mahid and Ishaq, Abbas and Freer, Matthew and Stebbings, Richard and Dickinson, Anne Mary},
title = {An In Vitro Human Skin Test for Predicting Skin Sensitization and Adverse Immune Reactions to Biologics},
journal = {Toxics},
year = {2024},
volume = {12},
number = {6},
pages = {401},
doi = {10.3390/toxics12060401}
}
EUVIMED